Yer link is to the “study” is NYT not CDC, just sayin, it’s paywalled.
COVID-19 stats and research news - until Nov. 15, 2021
- Thread starter MarzNC
- Start date
- Status
MarzNC
Well-known member
- Joined
- Jul 18, 2020
Wasn't that much in the CDC link or the article that seemed like new news except the graph I posted.
But if you want to see what CDC posted:
COVID Data Tracker
CDC’s home for COVID-19 data. Visualizations, graphs, and data in one easy-to-use website.
covid.cdc.gov
I've started a new volunteer project so not spending much time reading about the pandemic. There are assorted reasons this thread will time out and get locked in a couple weeks. Not just that my ski season will start with a 2000 mile drive to Colorado in early Dec.
sibhusky
Well-known member
- Joined
- May 12, 2021
Okay, maybe my side effects from changing horses were worth it. Sorry about the paywall. It wasn't there when I first read the article.
www.wsj.com
I had grabbed this before it showed up, as it applied to me:
Some one else grabbed the other charts for me. (thanks, Tom)
Covid-19 Vaccine Boosters’ Mix-and-Match Efficacy
Americans preparing to get a Covid-19 booster now can choose whether to stick with the same vaccine as their initial shots, or choose a different one. Here’s a look at advantages, disadvantages and side effects.
www.wsj.com
Some one else grabbed the other charts for me. (thanks, Tom)
Last edited:
Harvey
Administrator
- Joined
- Jul 15, 2020
Me too. Me three. Me four. Me five. ?
MarzNC
Well-known member
- Joined
- Jul 18, 2020
As I'm sure everyone already knows, kids ages 5-11 can get a Pfizer vaccination that's a smaller dose. Moderna is still working on the submission related to ages 6-11. I expect that will be available in early 2022, but could be a little earlier. I doubt there are that many parents who want to get younger kids vaccinated really care which mRNA vaccine they get before Thanksgiving and winter break.
October 29, 2021
www.fda.gov
www.cdc.gov
As of November, 5, 2021
October 29, 2021
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age
FDA authorized the emergency use of the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include children 5 through 11 years of age.
COVID-19 Vaccines for Children & Teens
CDC recommends everyone 5 years and older get a COVID-19 vaccination.
www.cdc.gov
gorgonzola
Well-known member
- Joined
- Jul 21, 2020
I guess this would go here, gonna get interesting...
Federal Register :: Request Access
www.federalregister.gov
Pfizer’s results from their own labs,
It’s a protease inhibitor.
Interim results were from a trial used in combo with another protease of theirs for high risk folks prior to hospitalization.
www.pfizer.com
It’s a protease inhibitor.
Interim results were from a trial used in combo with another protease of theirs for high risk folks prior to hospitalization.
Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study | Pfizer
PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19 In the overall study population through Day 28, no deaths were reported in patients who received PAXLOVID™ as compared to 10...
MarzNC
Well-known member
- Joined
- Jul 18, 2020
Will be a while (years?) before this research results in something available for people in general, but still interesting to know it's happening. My grad degree is from the UNC-Chapel Hill School of Public Health, so I'm on a mailing list for this sort of news. Fair to say that in 2020-21, most of the articles are related to the pandemic.
November 2, 2021
sph.unc.edu
"
A research collaboration between scientists at Duke University and the University of North Carolina at Chapel Hill has identified and tested an antibody that limits the severity of infections from a variety of coronaviruses, including those that cause COVID-19 as well as the original SARS illness.
The antibody was identified by a team at the Duke Human Vaccine Institute (DHVI) and tested in animal models at UNC-Chapel Hill. Researchers published their findings November 2 in the journal Science Translational Medicine.
“This antibody has the potential to be a therapeutic for the current epidemic,” said co-senior author Barton Haynes, MD, director of DHVI. “It could also be available for future outbreaks, if or when other coronaviruses jump from their natural animal hosts to humans.”
Haynes and colleagues at DHVI isolated the antibody by analyzing the blood from a patient who had been infected with the original SARS-CoV-1 virus — which caused the SARS outbreak in the early 2000s — and from a current COVID-19 patient.
They identified more than 1,700 antibodies, which the immune system produces to bind at specific sites on specific viruses to block the pathogen from infecting cells. When viruses mutate, many binding cites are altered or eliminated, leaving antibodies ineffectual. But there are often sites on the virus that remain unchanged despite mutations. The researchers focused on antibodies that target these sites because of their potential to be highly effective across different lineages of a virus.
. . ."
November 2, 2021
Duke, UNC-Chapel Hill scientists identify new antibody for COVID-19 and variants - UNC Gillings School of Global Public Health
November 2, 2021 A research collaboration between scientists at Duke University and the University of North Carolina at Chapel Hill has identified and tested an antibody that limits the severity of infections from a variety of coronaviruses, including those that cause COVID-19 as well as the...
sph.unc.edu
A research collaboration between scientists at Duke University and the University of North Carolina at Chapel Hill has identified and tested an antibody that limits the severity of infections from a variety of coronaviruses, including those that cause COVID-19 as well as the original SARS illness.
The antibody was identified by a team at the Duke Human Vaccine Institute (DHVI) and tested in animal models at UNC-Chapel Hill. Researchers published their findings November 2 in the journal Science Translational Medicine.
“This antibody has the potential to be a therapeutic for the current epidemic,” said co-senior author Barton Haynes, MD, director of DHVI. “It could also be available for future outbreaks, if or when other coronaviruses jump from their natural animal hosts to humans.”
Haynes and colleagues at DHVI isolated the antibody by analyzing the blood from a patient who had been infected with the original SARS-CoV-1 virus — which caused the SARS outbreak in the early 2000s — and from a current COVID-19 patient.
They identified more than 1,700 antibodies, which the immune system produces to bind at specific sites on specific viruses to block the pathogen from infecting cells. When viruses mutate, many binding cites are altered or eliminated, leaving antibodies ineffectual. But there are often sites on the virus that remain unchanged despite mutations. The researchers focused on antibodies that target these sites because of their potential to be highly effective across different lineages of a virus.
. . ."
MarzNC
Well-known member
- Joined
- Jul 18, 2020
Here's a visual on how a vaccine helps to keep SARS-CoV-2 from launching a major attack inside a human body. It was created by the Vaccine Makers Project (VMP). VMP is the classroom-based program of the Vaccine Education Center at the Children’s Hospital of Philadelphia (VEC at CHOP). The Center’s team is composed of scientists, physicians, mothers and fathers devoted to the study and prevention of infectious diseases.
Click to view on YouTube.
Click to view on YouTube.
- Status
